1. Scrip
  2. >>Business
  3. >>Deals

Yumanity To Reverse Merge With Kineta Two Years After Its Own Public Debut

 
• By Joseph Haas

After its August 2020 reverse merger, neuroscience-focused Yumanity is calling it quits with two transactions: an asset sale to Janssen and a merger with private cancer immunotherapy firm Kineta.

Concept Image For Deals
Yumanity is reverse merging with Kineta, enabling the latter to go public • Source: Alamy

Less than two years after going public via a reverse merger with troubled cystic fibrosis company Proteostasis Therapeutics, Inc., Yumanity Therapeutics, Inc. is winding up its operations by selling off its lead clinical candidate and preclinical neuroscience pipeline to Johnson & Johnson and merging with Kineta, Inc. in a transaction that will confer Yumanity’s NASDAQ listing to the privately held cancer immunotherapy firm.

Upon close of the all-stock transaction announced 6 June, the resulting company will be named Kineta Inc., based in Seattle and led by Kineta’s current management team. Kineta will focus...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

More from Business

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.